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Abstract
Cancer cells proliferate at rapid rates due to the aberrant activity of proteins involved in
regulating the cell cycle. This characteristic allows mutated cancer cells to spread and
metastasize, causing lesions to form throughout the body. Two treatment conditions, one
classical antifolate methotrexate (MTX) and non-classical, novel antifolate UCP1162, were
tested on a panel of acute myeloid leukemia (AML) cell lines to determine if UCP1162 has
higher anti-proliferative activity. High dose MTX is used as a first line chemotherapy in common
childhood malignancies such as acute lymphoid leukemia (ALL). Methotrexate is excluded from
acute myeloid leukemia (AML) treatments based on clinical trials that suggest AML cells are
intrinsically resistant. UCP1162, like MTX, targets dihydrofolate reductase (DHFR). UCP1162
does not appear to be limited by mutations of the reduced folate carrier (RFC) protein or folate
polyglutamate synthase (FPGS) since it is not expected to use these mechanisms. UCP1162 is
expected to accumulate better intracellularly and therefore, should provide more potent and
longer-lasting anti-proliferative effects. Another main focus is how the anti-proliferative activity
relates to the inhibition of nucleotide synthesis and DNA methylation. The comparison between
these two treatments can be assessed by assays that provide information on the resulting
cytotoxic effects. UCP1162 works with a lower EC50 than MTX, which may reduce cytotoxicity
and side effects, allowing this treatment to be more tolerable. If UCP1162 is proven to have
higher anti-proliferative effects than MTX, then it could play a key role in the arresting of cancer
cells and improving patient care.

Introduction
Leukemia and lymphoma
Leukemia and lymphoma are “blood-related” cancers that affect cells of the
hematopoietic lineage. These cancers of blood-forming cells differ from each other as well as
from solid tumors. Leukemia is cancer of the bone marrow, where the transformed leukemic
stem cells largely reside. Abnormal white blood cells are produced which no longer function
properly and, in turn, causes weakening of the immune system [1]. This diminished immune
response creates an opportunity for the cancer to spread through the human body faster and for
other acquired diseases to flourish. The four main groups of leukemia are: acute myelogenous
leukemia (AML), chronic, myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL)
and chronic lymphoblastic leukemia (CLL). Leukemia is one of the most common childhood
cancers, however, age ranges and symptoms have much overlap with lymphoma [2].

When compared with leukemia, lymphoma is any malignancy of the lymphocytes within
lymphoid tissue. This includes cells such as white cells that can accumulate in the thymus, bone
marrow, lymph nodes and spleen. The two groups of lymphoma are: Hodgkin Lymphoma (HL)
and non-Hodgkin lymphoma (NHL) [1]. The most common treatments for these hematologic
malignancies are: chemotherapy, targeted therapy, radiation therapy, stem cell transplantation
and surgery.

Leukemia occurs when one cell within the bone marrow mutates and becomes malignant
and then forms a cluster of cancerous cells and begins to grow and affect other parts of the body
through the bloodstream. The number of white blood cells drastically increase and overcrowd the
red blood cells and platelets that the body needs for physiological processes. The leukemia cells

migrate to lymphoid tissues and begin to affect the thymus, spleen and lymph nodes. As
mentioned, there are four main types to consider when diagnosing leukemia. Acute
lymphoblastic leukemia (ALL) is the most common childhood leukemia and has rapid
progression that affects the lymph nodes and central nervous system. Acute myeloid leukemia
(AML) is one of the most common forms of adult leukemia and also progresses rapidly, affecting
myeloid cells within the blood and bone marrow. Chronic lymphoblastic leukemia (CLL) is the
other most common form of adult leukemia, but grows much slower than ALL and AML,
beginning in the lymphocytes and spreading to the blood. Lastly, chronic myeloid leukemia
(CML) begins in the blood-forming cells, such as WBCs, and then spreads to blood from the
bone marrow. Each of these types of leukemia can be differentiated through blood tests, such as
a complete blood count (CBC), blood smears, bone marrow biopsies, spinal taps and imaging,
such as CT, MRI and PET scans. The cause of leukemia has not been identified, but evidence
points to genetic and environmental factors causing mutations in the DNA of blood cells [3].

Methotrexate: an anti-rheumatic and anti-neoplastic agent

Methotrexate is typically used to treat rheumatoid arthritis by preventing the antiinflammatory effects of the immune system. MTX enters the cell through RFC and is then
polyglutamated by FGPS. MTX-glutamate inhibits aminoimidazole carboxamide ribonucleotide
formyltransferase (AICART) and prevents the conversion of AICAR to 5-formamido imidazole4-carboxamide ribotide (FAICAR). This causes an overexpression of AICAR in the cell which
downstream leads to overexpressed AMP. AMP is transported extracellularly before a phosphate
group is lost to form adenosine. Extracellular adenosine signaling prevents excessive
inflammation by suppressing proinflammatory cytokines, inhibiting leukocyte entry into tissues

and triggering the production of anti-inflammatory cytokines. MTX has also been shown to have
anti-proliferative effects on AML cell lines due to inhibiting DHFR and downstream folatedependent enzymes thymidine synthase (TS) and aminoimidazole-4-carboxamide ribonucleotide
formyltransferase (AICARDT). This later causes blocking of dTMP, DNA synthesis and ATP
production [4]. However, AML cell lines are methotrexate-resistant and therefore, this should
not be used as a long-term treatment for patients experiencing this form of leukemia. Novel
UCP1162 is more hydrophobic than MTX and easily diffuses through the plasma membrane.
This allows UCP1162 to enter the cell without a carrier protein or channel, unlike folates and
MTX do through the RFC receptor. UCP1162 also does not require polyglutamation upon
entering the cell, so the FPGS enzyme is also not necessary for this treatment mechanism. This
allows UCP1162 to overcome the two resistance mechanisms that affect the MTX treatment
pathway and is more likely to be effective over long use when compared to MTX.

Antifolates are antimetabolites that target the folate metabolism, playing an important
role in treatment of malignant and chronic inflammatory diseases. The first antifolate studied was
aminopterin which supported remission from ALL in children. The remissions did not last but
this initiated optimism in the field because this disease was now known to be treatable.
Aminopterin was soon after replaced by methotrexate (MTX) due to its erratic toxic effects. The
mechanism of action under which MTX works was a slow discovery. Chemists were looking for
a ubiquitous antimetabolite to disrupt folate metabolism and treat cancer. It was unexpected
when the antifolate they designed became today's most well-known treatment for rheumatoid
arthritis. Pemetrexed was the next antifolate to be tested clinically which targets thymidylate
synthase and was used to treat patients with mesothelioma and non-small cell lung cancer. This
was followed closely by pralatrexate, in order to treat cutaneous T-cell lymphoma by blocking

dihydrofolate reductase [5]. However, mechanisms of these antifolates have shown significant
resistance and prevents these molecules from being considered an effective chemotherapeutic
agent for various cancers.

Figure 1. Folic acid and one-carbon metabolism.

The function of folate in one carbon metabolism, and the inhibition of one carbon
metabolism by MTX is shown in Figure 1. Folate, also known as Vitamin B9, is not produced
within the body so it must be acquired through dietary sources. It enters into the cell through the
reduced folate carrier (RFC). Once inside the cell, folate is then reduced to dihydrofolate (DHF)
by the enzyme dihydrofolate reductase through the oxidation of NADPH to NADP+. This redox

reaction occurs again to convert DHF to tetrahydrofolate (THF) through the same enzyme. The
enzyme serine hydroxyl methyl transferase (SHMT) converts THF to N5, N10-methylene THF.
This enzyme requires a serine that will donate a hydroxyl and methyl group, resulting in a
glycine amino acid, and also pyridoxal phosphate, a cofactor and derivative of Vitamin B6.
SHMT is a reversible enzyme therefore if glycine is readily available, then excess N5, N10methylene THF can be converted back to THF until needed by the cell. N5, N10-methylene THF
can now be recycled back to DHF by the enzyme thymidylate synthase. This enzyme is critical
because it converts deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate
(dTMP) through the reduction of an FADH2 to FAD and dTMP is utilized for DNA synthesis.
However, N5, N10-methylene THF in excess can also be acted on by the enzyme methyl
tetrahydrofolate dehydrogenase (MTHFD) through the oxidation of NADPH to NADP+
resulting in N5, N10-methenyl THF. This molecule is then converted to N10-Formyl THF by
methenyl tetrahydrofolate cyclohydrolase (MTHFC) which requires a water molecule to
function. The final N10-Formyl THF can then be utilized for purine synthesis and therefore,
DNA replication [6]. When methotrexate is administered, it works as an inhibitor of DHFR,
which prevents folate from becoming THF. This prevents all of the later pathways in the folate
cycle and therefore, disrupts DNA synthesis and replication.

Advantages of UCP1162 as an anti-folate

Methotrexate can enter the cell the same way as folate, through its RFC receptors. It can
also diffuse intracellularly by other active transporters, such as folate receptor alpha and proton
coupled folate transporter, that work based on the cell’s pH gradient. Once in the cytoplasm, the
folylpolyglutamate synthase (FPGS) enzyme converts MTX to methotrexate polyglutamate

(MTX-PG). This is the activated form of methotrexate which can then go on to inhibit many
cellular processes, such as purine synthesis, dTMP availability required for DNA synthesis, and
all later transmethylation reactions by blocking the activity of the DHFR enzyme. Methotrexate
has been used for decades as a therapeutic agent for multiple cancer types, however, its
resistance mechanism proves it to be a less efficient treatment. The mechanism of resistance
results in decreased cellular uptake of MTX, increased intracellular levels of the DHFR enzyme,
down-regulation of RFC genes and an inconsistent rate of MTX polyglutamation [4]. Therefore,
a new therapeutic treatment without resistance is a desired and novel UCP1162 has shown
promising results as a replacement to MTX. UCP1162 overcomes resistance mechanism by
passively diffusing across the membrane due to its high hydrophobicity, avoiding the RFC
receptor pathway. It is also likely that it doesn’t require poly-glutamation because it does not
have a glutamate residue.

Molecular defects and treatments for AML

Some cases of AML have been shown to arise from rearrangements of the MLL gene.
The most common MLL translocation partner proteins (AF4, AF9, ENL, and ELL) recruit the
transcriptional activation complex, p-TEFb (cyclin T1 and CDK9), and initiates transcriptional
elongation through polymerase II (Pol II). These MLL fusion proteins also interact with the
histone H3K79 methyltransferase DOT1L which causes abnormal transcriptional activation of
MLL target genes [7]. MLL translocation in AML cells causes expression of genes associated
with stem cell-like phenotypes, which drives the aggressive growth of cancer cells. Therefore,
UCP1162 is likely to suppress the aberrant methylation of MLL-target genes in AML cells due

to the reduction of the methyl donor pool [8]. This reduction in methylation may irreversibly
differentiate the AML cells in order to stop their growth.

Current treatments for AML include: chemotherapy, targeted therapy, radiation therapy
and/or stem cell transplants. Intensive chemotherapy is the most common treatment method for
AML and is administered typically intravenously in order to enter the bloodstream directly. This
treatment plan can be divided into three phases consisting of induction therapy, post-remission
therapy and consolidation therapy. The adverse effects of chemotherapy can be devastating due
to healthy cells and tissues also being affected. Targeted therapy is more complex and isolates
the specific genes and proteins correlated with leukemia, in order to spare healthy tissue. An
issue with this treatment is that not all cancers have a similar target gene or protein and it has
been proven that many cancer cell lines affect a large number of these factors. AML affects the
IDH1, IDH2 and FLT3 genes of leukocytes, however, it is believed that other genes are also
being affected. Lastly, is radiation therapy, in which external beam radiation is used to stop the
growth of cancer cells. The side effects are less debilitating than chemotherapy, but this
treatment is typically only used when cancerous cells travel through the bloodstream and make
their way to the brain [9]. There is currently no treatment for AML that is both effective and well
tolerated.

Materials & Methods

Cell growth and treatment

Four different cell lines obtained from American Type Culture Collection (ATCC) were
grown in specific media solutions. Media, PBS and TrypLE were purchased from ThermoFisher.

HCT116, a human colon cancer cell line, was grown in McCoy’s media supplemented to a final
concentration of 10% FBS, 1% anti anti and 1% non-essential amino acid. HCT116 is an
epithelial cell line with adherent character. Therefore, a sterile PBS wash and TrypLE are
required in order to pass these cells. CCRF-CEM, is a human T lymphoblast cell line that is
grown in suspension in RPMI 1640 media supplemented to a final concentration of 10% FBS,
1% anti anti and 1% non-essential amino acid. These cells are acute lymphoblastic leukemia
(ALL) cells. These cell lines were tested in order to see if UCP1162 is generally antiproliferative to other types of cancer. The two cell lines categorized under acute myeloid
leukemia (AML) and grown in suspension were THP-1 and MV-4-II. MV-4-II lymphoblasts
were grown in RPMI 1640 media supplemented to a final concentration of 10% FBS, 1% anti
anti and 1% non-essential amino acid. Lastly, THP-1 monocytes were grown in RPMI 1640
media supplemented to a final concentration of 10% FBS, 0.05 mM 2mercaptoethanol, 1% anti
anti and 1% non-essential amino acid.

These cell lines were plated in T25 or T75 cell culture flasks. Each cell line was kept
incubated at 37oC and 5% CO2 incubator. Cells were seeded at 2-3x10^5 cells/mL and grown up
to 2-3X10^6 cells/mL. This required the flasks to be passed every 3-4 days. Cell counting was
performed by a Countess II automated cell counter (ThermoFisher). The appropriate media in the
fridge was warmed to 37oC in the incubator for approximately 20 minutes before any procedure.
The culture hood was turned on and sterilized with 70% ethanol before removing the flasks from
the incubator and placing them in the hood. In the flasks, 4.5 milliliters of the appropriate fresh
media were added, following with 0.5 milliliter of the cell suspension. These cells were passed
every 3-4 days or when the cells looked confluent under a microscope.

When passing the cells lines, the old media was removed with a serological pipette and
discarded into the liquid waste container. For the HCT116 cells, after all the media was removed,
the flask was first washed with sterile PBS and then TrypLE was added to the flask. The TrypLE
was moved around the flask mechanically for 1-2 minutes or until the bottom of the flask became
clear. This step was required for the HCT116 cell line because they are adherent cells. To this, 4
mL of fresh media were added to the flask. The other three cell lines were grown in suspension
so PBS wash and TrypLE were not used. Instead, the suspension cells were passed by adding
suspension cells into a fresh, prewarmed media directly. The flasks were then returned to the
incubator and the hood was sterilized after use.

Cell viability and ATP quantification

An ATP assay (ATP Determination Kit: A22066) and MTS viability were run in parallel
to confirm that the given concentrations of MTX and UCP1162 were able to reduce the viability
(anti-proliferative). The reduction of viability is directly proportional to the reduction of ATP
levels. This reduction also confirms that the tested compound is functioning through the folate
pathway and therefore, has antifolate action. For the ATP assay, cells were treated in 24-well
plates overnight. The Mammalian Protein Extraction Reagent (MPER) extraction protocol was
followed. Ninety microliters of the lysed cell extracts were added into the wells of the black 96well plate. Ten microliters of ATP reaction solution were added on top of the sample extracts.
Each well was mixed thoroughly with a multichannel pipette and then, the luminescence was
read immediately using a plate reader. This bioluminescence assay quantifies ATP production
through the use of firefly luciferase and its substrate D-luciferin. The resulting luminescence
values were normalized to either nucleic acid or protein concentration of the samples measured

by a nanodrop instrument. A standard curve is created of luminescence versus ATP produced
(picomoles) to find the concentration at which the greatest amount of ATP is produced.

The MTS assay is a colorimetric method used to determine the number of viable cells in
cell culture. The assay is effective through dye reduction that provides information about
cytotoxicity/anti-proliferative activity. The MTS reagent in the assay is reduced by the viable
cells in the sample, which produces a colorful product that can be quantified at 490nm in a plate
reader. For the MTS assay, a 96-well Falcon clear plate was used. A ten microliter sample of the
flask was used to find the cell density. The target seeding density was 5x10^5 cells/mL. Using
the formula, C1V1=C2V2, the appropriate volume was calculated and taken from the flask of
cells and added to excess media in an aliquot tube in order to yield an optimal cell number in
each well. Forty-eight wells were filled with one hundred microliters of this mixture in the
aliquoted tube, one well with 100 microliters of the media that cell line was grown in and the rest
with 100 microliters of distilled water. There were seven concentrations tested for each treatment
and dmso was used as a control. Each concentration for each treatment and the controls were
performed in triplets. The final concentrations of MTX were: 2.5 nM, 5 nM, 10 nM, 20 nM, 40
nM, 80 nM and 160 nM. The final concentrations of UCP1162 were: 0.3375 nM, 0.675 nM 1.25
nM, 2.5 nM, 5 nM, 10 nM and 20 nM. No treatment or dmso was added to the media control
well. This plate was treated for approximately 48 hours before proceeding.
The CellTiter 96 AQ-One Solution Reagent was removed from the -20oC refrigerator and
thawed for 15 minutes in a 37oC incubator. A multi-channel pipette was used to add 20
microliters of the CellTiter Solution to each of the wells, including the well that just contained
culture medium. This is a colorimetric time-dependent assay so the multi-channel pipette was

used to produce uniform volumes in a shorter amount of time than an individual micropipette.
The plate went back into the incubator for 1.5 hours or until the wells began to turn dark yellow
in color. The absorbance was recorded at 490nm using a plate reader and the A490 values are
directly proportional to the number of viable cells. The data was averaged for each treatment
concentration and normalized to the media control before being graphed. From this data, we can
determine the EC50 value of MTX and UCP1162 and therefore, compare the effectiveness of
both using GraphPrism dose response curve fitting.

Cell cycle analysis

Flow cytometry is a technique used to express and determine both physical and chemical
characteristics present within a population of cells. This method is one of the ways to do cell
cycle analysis through the quantification of DNA content. DNA is stained by DNA binding dyes
and they bind proportionally to the amount of DNA found in the cell and therefore fluoresce
more brightly. This allows us to quantify the numbers and percentages of cells in the G1, S or
G2/M phase. It is expected that the G2/M phase should fluoresce more brightly, followed by the
S phase, since more DNA is found at these phases than the G1 phase. This enables us to
characterize these cancer cell lines further and determine where each treatment is causing the
cells to arrest their growth within the cell cycle and therefore slow tumor progression.

Results

Cell viability EC50 determination

The ATP response after a 24-hour treatment of MTX/UCP1162 can be seen in Figures 23. The ATP assay and MTS viability were run in parallel to confirm that the given concentrations

of MTX and UCP1162 were anti-proliferative and effective in resulting in a loss of viable cells.
The cell viability per A490 nm versus the concentration of MTX/UCP1162 treatment can be seen
in Figures 4-7. Using GraphPrism, these dose-response curves were generated and fitted using
“dose-response-stimulation.” The EC50 of each treatment was calculated and reported. Each
graph represents the average cell viability in triplets from two separate MTS assay runs, except
for Figure 7 in which MTS assay in triplets were run once. For Figure 4, when tested on the
HCT116 cell line, the EC50 of MTX was 24.2nM while the EC50 for UCP1162 was 3.3nM. For
Figure 5, when tested on the CCRF-CEM cell line, the EC50 of MTX was 5.6nM while the
EC50 for UCP1162 was 1.2nM. For Figure 6, when tested on the THP-1 cell line, the EC50 of
MTX was 21.9nM while the EC50 for UCP1162 was 1.6nM. For Figure 7, when tested on the
MV-4-II cell line, the EC50 of MTX was 5.15nM while the EC50 for UCP1162 was 0.78nM.
For all cell lines tested, including the adherent human colon cancer cell line and suspension ALL
and AML cell lines, the EC50 for UCP1162 was significantly lower than that of MTX.

ATP assay

Figure 2. ATP assay showing decreased intracellular ATP levels for HCT116 cells when treated
with MTX/UCP1162 for ~24 hours.

Figure 3. ATP assay showing decreased intracellular ATP levels for CCRF-CEM cells when
treated with MTX/UCP1162 for ~24 hours.

MTS viability

Figure 4. MTS cell viability assay performed on HCT116 cells treated with serial concentrations
of MTX or UCP1162 for ~48 hours.

Figure 5. MTS cell viability assay performed on CCRF-CEM cells treated with serial
concentrations of MTX or UCP1162 for ~48 hours.

Figure 6. MTS cell viability assay performed on THP-1 cells treated with serial concentrations
of MTX or UCP1162 for ~48 hours.

Figure 7. MTS cell viability assay performed on MV-4-II cells treated with serial concentrations
of MTX or UCP1162 for ~48 hours.

Cell cycle analysis

The fluorescence measured as a result of DNA content is shown in Figures 8-10. These
graphs were analyzed by a flow cytometry software in order to calculate the percentage of viable
cells in each phase of the cell cycle. Flow analysis was not performed for the MV-4-II cell line.
In Figure 8, the untreated HCT116 cell line shows 47.5% of viable cells in the G1 phase, 32.9%
in the S phase and 16.5% in the G2 phase. When treated with 160nM of MTX, the HCT116 cells
expressed 51.0% of viable cells in the G1 phase, 42.2% in the S phase and 3.97% in the G2
phase. When treated with 20nM of UCP1162, the HCT116 cells expressed 47.1% of viable cells
in the G1 phase, 44.4% in the S phase and 6.0% in the G2 phase. In Figure 9, the untreated
CCRF-CEM cell line shows 17% of viable cells in the G1 phase, 11% in the S phase and 38% in
the G2 phase. When treated with 160nM of MTX, the CCRF-CEM cells expressed 23% of viable
cells in the G1 phase, 11% in the S phase and 41% in the G2 phase. When treated with 20nM of
UCP1162, the CCRF-CEM cells expressed 20% of viable cells in the G1 phase, 11% in the S

phase and 42% in the G2 phase. In Figure 10, the untreated THP-1 cell line shows 65% of viable
cells in the G1 phase, 17% in the S phase and 17% in the G2 phase. When treated with 160nM of
MTX, the THP-1 cells expressed 65% of viable cells in the G1 phase, 24% in the S phase and
10% in the G2 phase. When treated with 20nM of UCP1162, the THP-1 cells expressed 64% of
viable cells in the G1 phase, 27% in the S phase and 9% in the G2 phase. Overall, these data
point to an S-phase arrest by both UCP1162 and MTX for HCT116 and THP-1 cells. Data for the
CCRF cells is more difficult to interpret, as this cell line appeared to be composed of both
diploid and stable tetraploid lines.

Flow cytometry

Figure 8. Cell cycle analysis by PI staining followed by flow cytometry run. The experiment
performed on HCT116 cells treated with a single concentration of MTX or UCP1162 for ~ 24
hours.

Figure 9. Cell cycle analysis by PI staining followed by flow cytometry run. The experiment
performed on CCRF-CEM cells treated with a single concentration of MTX or UCP1162 for ~
24 hours.

Figure 10. Cell cycle analysis by PI staining followed by flow cytometry run. The experiment
performed on THP-1 cells treated with a single concentration of MTX or UCP1162 for ~ 24
hours.

Discussion
MTX has been used for decades as an antineoplastic and anti-inflammatory agent.
However, resistance to MTX is an important concern that limits its clinical use. In the studies
described here, MTX is compared to a newly developed antifolate, UCP1162, focusing on cell

proliferation and ATP synthesis. The ATP assay and MTS viability assay were run in parallel to
confirm that the given concentrations reduced cellular viability (anti-proliferative) concomitant
with the reduction of ATP levels. The reduction of viability is directly proportional to the
reduction of ATP levels. Both UCP1162 and MTX decreased cellular ATP levels with similar
dose-response profiles, consistent with an antifolate activity of UCP1162.
The EC50 is the dose required to reach 50% of the drug’s maximum effect. From a
pharmacological and clinical perspective, it is more desirable to administer a drug with a lower
EC50 since a more potent compound is less likely to cause undesirable off-target side-effects.
For all cell lines tested, the EC50 for UCP1162 was significantly lower than MTX, indicating
UCP1162 is a stronger anti-proliferative. The lower EC50 should allow a lower dose of
treatment for UCP1162 relative to MTX. This data indicates that UCP1162 may be a more
desirable treatment than MTX to treat various forms of leukemia.
Flow cytometry was used to find the percentage of viable cells arrested in each phase of
the cell cycle by MTX and UCP1162. With the exception of the CCRF-CEM cell line, both
UCP1162 and MTX treatment caused cells to accumulate in S-phase. This is consistent with the
depletion of dNTP pools resulting from inhibited nucleotide synthesis, resulting in cells running
out of nucleotides causing an S-phase blockage to occur. This shows that UCP1162 and MTX
work through a similar growth inhibition mechanism, and provides additional evidence that
UCP1162 works through an antifolate mechanism.
UCP1162 follows a similar mechanism to MTX by inhibiting DHFR and downstream
prevention of DNA replication. However, UCP1162 is expected to not be affected by the many
resistance mechanisms that limit MTX due to not being involved in FPGS modifications. It is
also likely to have fewer side effects due to a lower EC50, which also points to it being more

effective. Moving forward, the focus of UCP1162 development is to provide therapeutic relief to
patients suffering with AML and possibly other forms of cancer. The next step is to determine
the safe maximum UCP1162 concentration and stability in vivo. Following this we would like to
see whether UCP1162 can drive MLL mutant AML cells to terminally differentiate with
UCP1162 since aberrant histone methylation is thought to be critical for maintaining MLL
mutant leukemias in a stem cell state. Another direction might be use of a DNA methylation
antibody with a confocal microscope to determine how UCP1162 affects DNA methylation.
Novel UCP1162 has proven to be a promising therapeutic with distinct chemical properties that
may ultimately serve as a useful tool for patient treatment.
Acknowledgements
This thesis and the research behind it would not have been possible without the support
of my principle investigator, Dr. Charles Giardina, and graduate teaching assistant, Didem
Ozcan. I would like to thank Dr. Giardina for allowing me to continue to expand my knowledge
of cancer research under his supervision and project idea. I would also like to thank Didem
Ozcan for providing me with the ATP assays, MTS assays and flow analysis’ performed on the
HCT116 and CCRF-CEM cells (shown in Figures 2-5 & 8-9) as well as the folate one-carbon
metabolism diagram (shown in Figure 1). Dr. Giardina and Didem have each spent countless
time mentoring me throughout my undergraduate laboratory career and have provided me the
confidence necessary to pursue other research projects in my future.

References
1. Guillerman, R Paul, Stephan D Voss, and Bruce R Parker. "Leukemia and Lymphoma."
Radiologic Clinics of North America 49.4 (2011): 767-97, Vii. Web.
2. Mackey, Heather Thompson, and Paula Klemm. "Leukemia." The American Journal of
Nursing 100.4 (2000): 27-31. Web.
3. Popat, Uday. Leukemia. 1st ed. Demos, 2011. Web.
4. Castillo, Valentina S., and Laura A. Moyano. Methotrexate Pharmacology, Clinical Uses
and Adverse Effects. Hauppauge, N.Y.: Nova Science, 2012. Pharmacology-research,
Safety Testing, and Regulation Ser. Web.
5. Visentin, Michele, Rongbao Zhao, and I. David Goldman. "The
Antifolates." Hematology/Oncology Clinics of North America 26.3 (2012): 629-48. Web.
6. Lynn B. Bailey, Jesse F. Gregory, III, Folate Metabolism and Requirements, The Journal
of Nutrition, Volume 129, Issue 4, April 1999, Pages 779–
782, https://doi.org/10.1093/jn/129.4.779
7. Chang, Ming-Jin, Hemenway, Charles, Blake, Diane, Landry, Samuel, Miller, Charles,
and Zeleznik-Le, Nancy. Characterization of Specific Roles for AF4 and Dot1 in
Transformation Mediated by MLL-AF9 Leukemic Oncoprotein (2011): ProQuest
Dissertations and Theses. Web.
8. Winters, Amanda C., and Kathrin M. Bernt. "MLL-Rearranged Leukemias—An Update
on Science and Clinical Approaches." Frontiers in Pediatrics 5 (2017): 4. Web.
9. Garza, Juan M. Acute Myeloid Leukemia: Signs/symptoms, Classification and Treatment
Options. 2015. Cancer Etiology, Diagnosis, and Treatments. Web.

